Welcome to our dedicated page for Emmaus Life Scie news (Ticker: EMMA), a resource for investors and traders seeking the latest updates and insights on Emmaus Life Scie stock.
Emmaus Life Sciences, Inc. (NASDAQ: EMMA) is a commercial-stage biopharmaceutical company pioneering treatments for rare diseases, with a focus on sickle cell disease therapy Endari®. This page serves as the definitive source for official company announcements, regulatory developments, and research breakthroughs.
Investors and stakeholders can access timely updates on clinical trial progress, FDA/EMA filings, manufacturing expansions, and strategic partnerships. Our curated news collection provides transparent insights into EMMA's operational milestones without speculative commentary.
Key content includes updates on global regulatory approvals, peer-reviewed study publications, supply chain optimizations, and intellectual property developments. All information is sourced directly from company filings and verified industry channels.
Bookmark this page for streamlined access to Emmaus Life Sciences' latest advancements in orphan drug development. Check regularly for updates that matter to healthcare professionals, patients, and financial stakeholders alike.
Emmaus Life Sciences (OTCQB: EMMA) reported its 2024 financial results, showing significant challenges throughout the year. The company experienced a 43.6% decline in net revenues to $16.7 million (vs $29.6 million in 2023), primarily due to inventory shortages during early to Q3 2024.
Despite reducing operating expenses by nearly 30% to $17.3 million through decreased headcount and suspended R&D activities, the company recorded a loss from operations of $1.9 million compared to an income of $3.5 million in 2023. The net loss increased to $6.5 million ($0.10 per share) from $3.7 million ($0.07 per share) in 2023.
Cash position decreased to $1.4 million by year-end 2024, down from $2.5 million in 2023. Management expects 2025 revenues to reach or exceed 2024 levels, citing sufficient inventory for the year barring unexpected developments.
Emmaus Life Sciences (OTCQB: EMMA) announced that its sickle cell disease treatment, Endari® (L-glutamine oral powder), has been granted market exclusivity in the Kingdom of Saudi Arabia (KSA) by the National Uniform Procurement Agency (NUPCO). The initial exclusivity period is one year, with potential extension to three years upon marketing registration approval.
The exclusivity applies across all KSA government institutions, including Ministry of Health hospitals, Military Hospitals, National Guard, Security Forces, and King Faisal Specialty Hospitals and Research Centers. This represents a significant opportunity in the KSA's healthcare system for treating sickle cell disease patients.
Emmaus Life Sciences (OTCQB: EMMA) reported Q3 2024 financial results with net revenues of $5.5 million, up 9% from Q3 2023, and net income of $1.8 million, a 2,626% increase. The company resumed inventory production in August, leading to improved quarterly performance. However, year-to-date net revenues decreased 41% due to earlier inventory shortages. Operating expenses decreased to $4.3 million in Q3 2024 from $4.8 million in Q3 2023. The launch of a competing generic L-Glutamine Oral Powder in July may impact future Endari sales. Cash position stood at $1.3 million as of September 30, 2024.
Emmaus Life Sciences (OTC: EMMA) reported financial results for Q1 and Q2 2024. Key points:
- Net revenues for H1 2024 were $7.9 million, down 55% from $17.5 million in H1 2023 due to inventory shortages.
- Operating loss of $2.2 million in H1 2024, compared to $2.2 million income in H1 2023.
- Net loss of $6.5 million ($0.10 per share) in H1 2024, versus $5.0 million loss in H1 2023.
- Cash and equivalents of $1.5 million as of June 30, 2024.
The company doesn't expect 2024 full-year revenues to reach 2023 levels. It's working with alternative manufacturers to avoid future shortages and assessing the impact of a new generic competitor.
Emmaus Life Sciences (OTCMarkets: EMMA), a leader in sickle cell disease treatment, has appointed Willis C. Lee as its new Chief Executive Officer. Lee, previously serving as Co-President and Chief Operating Officer, will retain his position as Chairman of the Board. The company is focusing on improving operational efficiency and preparing for challenges posed by the launch of generic L-glutamine.
Lee emphasized plans to grow market presence in the Middle East and invest in research to expand pipelines and increase company value. He committed to working closely with the Board, restructured teams, and stakeholders to justify their trust in the company's future.
Emmaus Life Sciences (OTCPK: EMMA), a leader in sickle cell disease treatment, announced receiving a 'No Action Indicated' (NAI) classification following a routine FDA inspection of its Postmarketing Adverse Drug Experience (PADE) compliance program. This signifies no objectionable conditions or practices were found in the six years since Endari® has been marketed. This classification places Emmaus within the top 16% of companies inspected in 2019, highlighting their commitment to high-quality and safe medications. The inspection, conducted by two FDA Consumer Safety Officers over two and a half days, underscores Emmaus' dedication to regulatory compliance and patient safety.
Emmaus Life Sciences (OTCPK: EMMA), a biopharmaceutical company specializing in sickle cell disease treatment, released its 2023 financial results. The company reported a 61% increase in annual net revenues, reaching $29.6 million, driven by higher sales in the MENA region and the U.S. Income from operations rose to $3.5 million from a loss of $6.6 million in 2022. However, the net loss was $3.7 million, a notable improvement from the $10.6 million loss in 2022. The company faced a slowdown in Endari sales in Q4 2023 due to inventory shortages, impacting sales in Q1 and Q2 2024. Emmaus has since addressed the shortage and is working with alternative manufacturers. Operating expenses increased to $24.7 million from $22.4 million in 2022, primarily due to higher administrative and selling expenses. The company held $2.5 million in cash and cash equivalents as of December 31, 2023.
FAQ
What is the current stock price of Emmaus Life Scie (EMMA)?
What is the market cap of Emmaus Life Scie (EMMA)?
